Health and Fitness Health and Fitness
Thu, January 6, 2011
[ Thu, Jan 06th 2011 ] - Market Wire
Vertex Pharmaceuticals Announces Webcast of its P .. the 29th Annual J.P. Morgan Healthcare Conference
[ Thu, Jan 06th 2011 ] - Market Wire
SurModics and Ramius Reach Agreement Regarding 2011 Annual Meeting of Shareholders
[ Thu, Jan 06th 2011 ] - Market Wire
XIFAXAN® 550 mg Tablets Demonstrated Significant .. Irritable Bowel Syndrome Without Constipation Ac
[ Thu, Jan 06th 2011 ] - Market Wire
Covidien Announces the Availability of Nellcora" .. with Drger Infinity® Acute Care System in Europe
[ Thu, Jan 06th 2011 ] - Market Wire
Celgene annonce le d©p't de soumissions r©glementaires
[ Thu, Jan 06th 2011 ] - Market Wire
Biogen Idec nomina Doug Williams responsabile del .. Steven Holtzman a capo del Corporate Development
[ Thu, Jan 06th 2011 ] - Market Wire
Covidien kondigt beschikbaarheid aan van Nellcora .. met Drger Infinity® Acute Care System in Europa
[ Thu, Jan 06th 2011 ] - Market Wire
Covidien annuncia la disponibilit della tecnologi .. l'Infinity® Acute Care System di Drger in Europa
[ Thu, Jan 06th 2011 ] - Market Wire
Biogen Idec ernennt Doug Williams zum Leiter der .. bteilung und Steven Holtzman zum Leiter der Unter
[ Thu, Jan 06th 2011 ] - Market Wire
Covidien meldet die Verfgbarkeit der Nellcora" Ox .. standteil des Infinity® Acute Care Systems von D
[ Thu, Jan 06th 2011 ] - Market Wire
Biogen Idec stelt Doug Williams aan als hoofd O&O .. n Steven Holtzman als hoofd Corporate Development
Wed, January 5, 2011
[ Wed, Jan 05th 2011 ] - Market Wire
Santarus and Depomed Announce Availability of GLUMETZA 500 mg Tablets
[ Wed, Jan 05th 2011 ] - Market Wire
SuperGen Announces Enrollment of First Patient in .. in Human Trial of SGI-110 in MDS and AML Patients
[ Wed, Jan 05th 2011 ] - Market Wire
ANGIOTECH PHARMACEUTICALS ANNOUNCES NOTICE OF DELISTING FROM THE NASDAQ STOCK MARKET
[ Wed, Jan 05th 2011 ] - Market Wire
Positive Phase II Results with Iniparib (BSI-201) .. ple Negative Breast Cancer Published in The New E
[ Wed, Jan 05th 2011 ] - Market Wire
Medtronic Announces $750,000 in Funding to Support Healthcare Infrastructure Development in Haiti
[ Wed, Jan 05th 2011 ] - Market Wire
Hythiam Announces Catasys Contract with Coventry Health Care, Inc. Unit
[ Wed, Jan 05th 2011 ] - Market Wire
CEO of ARCA biopharma to Speak on Cardiovascular .. Medicine at Personalized Medicine Coalition Confe
[ Wed, Jan 05th 2011 ] - Market Wire
St. Jude Medical Announces Fourth Quarter and Full-Year 2010 Earnings Conference Call
[ Wed, Jan 05th 2011 ] - Market Wire
LabCorp is Scheduled to Present at the 29th Annual J.P. Morgan Healthcare Conference
[ Wed, Jan 05th 2011 ] - Market Wire
LifePoint Hospitals to Participate in 29th Annual J.P. Morgan Healthcare Conference
[ Wed, Jan 05th 2011 ] - Market Wire
Almirall and Forest Announce Positive Results fro .. of Aclidinium Bromide and the Phase IIb Studies w
[ Wed, Jan 05th 2011 ] - Market Wire
AngioDynamics Reports Fiscal 2011 Second Quarter Financial Results
[ Wed, Jan 05th 2011 ] - Market Wire
Alkermesa? Corporate Presentation to be Webcast at the JPMorgan Healthcare Conference
[ Wed, Jan 05th 2011 ] - Market Wire
Celgene ofrece nuevos datos sobre presentaciones normativas
[ Wed, Jan 05th 2011 ] - Market Wire
Celgene komt met update over het indienen van reglementaire aanvragen
[ Wed, Jan 05th 2011 ] - Market Wire
NeuroMetrix Announces New Strategic Direction
[ Wed, Jan 05th 2011 ] - Market Wire
Thermo Fisher Scientific to Present at the 29th A .. PMorgan Healthcare Conference on January 11, 2011
[ Wed, Jan 05th 2011 ] - Market Wire
InSite Vision Completes Patient Enrollment in ISV .. Study for Post-Surgical Ocular Pain and Swelling
[ Wed, Jan 05th 2011 ] - Market Wire
MannKind to Present at the JP Morgan 29th Annual HealthcareConference

MannKind to Present at the JP Morgan 29th Annual HealthcareConference


Published on 2011-01-05 09:30:38 - Market Wire
  Print publication without navigation


VALENCIA, Calif.--([ BUSINESS WIRE ])--MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the JP Morgan Healthcare Conference on Wednesday, January 12, 2011 at 3:00 PM (PT) at the Westin St. Francis Hotel in San Francisco, California.

Interested parties can access a link to the live webcast of the presentation from the News & Media section of the Company's website at [ http://www.mannkindcorp.com ].

About MannKind Corporation

MannKind Corporation (NASDAQ:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFREZZA® and MKC253. MannKind has submitted a NDA to the FDA requesting approval of AFREZZA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MKC253 is currently in phase 1 clinical trials. Other products in MannKind's pipeline include the cancer immunotherapy platform MKC1106, which is currently in phase 2 clinical trials. MannKind maintains a website at [ http://www.mannkindcorp.com ] to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Contributing Sources